The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen's Imdelltra and AstraZeneca's Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial therapy.
Beyond overall survival, the combination also improved progression-free survival and response rates, with no new safety concerns identified. For Amgen, the result is particularly relevant because Imdelltra generated $513 million in sales last year and could now have a broader role in the treatment of small-cell lung cancer.
For Amgen Inc. (NASDAQ:AMGN), the biggest limitation is that the positive trial result does not automatically translate into a blockbuster revenue opportunity for Imdelltra. The drug generated $513 million in sales last year, meaning the company would need substantial uptake in the maintenance setting to make the trial financially material relative to Amgen's overall scale. Competition in oncology is also intense, and physicians may weigh the incremental survival benefit, treatment complexity, safety, and reimbursement before broadly adopting the combination. In addition, Amgen's investment case is much broader than Imdelltra, so even a strong commercial launch may have only a modest impact on the company's total earnings unless the drug becomes a much larger contributor.
Overall, the trial is clearly positive for both stocks, but the impact is more about strengthening their long-term oncology franchises than immediately transforming their earnings outlook. Amgen Inc. (NASDAQ:AMGN) gets a meaningful validation of Imdelltra and a potential path to expanding the drug's commercial reach, while AstraZeneca PLC (NYSE:AZN) gets another piece of evidence supporting its broader oncology strategy and Imfinzi franchise.